ScholarIQanswers from OpenAlex & ORCID
Ana Oaknin
ResearcherPublications, citations & collaboration network
Ana Oaknin is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Ana Oaknin have?
ScholarIQindexed works
Ana Oaknin has 720 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Ana Oaknin have?
ScholarIQcitation count
Ana Oaknin has 37,502 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Ana Oaknin?
ScholarIQh-index
Ana Oaknin has an h-index of 73 in OpenAlex.
What is the i10-index of Ana Oaknin?
ScholarIQi10-index
Ana Oaknin has an i10-index of 214 in OpenAlex.
What is the ORCID of Ana Oaknin?
ScholarIQorcid
The ORCID for Ana Oaknin is on the source record.
What is the OpenAlex record for Ana Oaknin?
ScholarIQopenalex
The OpenAlex for Ana Oaknin is on the source record.
What are the most-cited papers on Ana Oaknin?
ScholarIQmost cited works
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Kathleen N. Moore, Nicoletta Colombo, Giovanni Scambia, Byoung‐Gie Kim, Ana Oaknin, Michael Friedländer, Alla Lisyanskaya, Anne Floquet, Alexandra Léary, Gabe S. Sonke, Charlie Gourley, Susana Banerjee, Amit M. Oza, Antonio González-Martı́n, Carol Aghajanian, William H. Bradley, Cara Mathews, Joyce F. Liu, Elizabeth Lowe, Ralph Bloomfield, Paul DiSilvestro
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
M. William Audeh, James Carmichael, Richard T. Penson, Michael Friedländer, Bethan Powell, Katherine M. Bell‐McGuinn, Clare L. Scott, Jeffrey N. Weitzel, Ana Oaknin, Niklas Loman, Karen H. Lu, Rita K. Schmutzler, Ursula A. Matulonis, Mark Wickens, Andrew Tutt
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L. Coleman, Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean, Nicoletta Colombo, Johanne I. Weberpals, Andrew R. Clamp, Giovanni Scambia, Alexandra Léary, Robert W. Holloway, Margarita Amenedo, Peter C.C. Fong, Jeffrey C. Goh, David M. O’Malley, Deborah K. Armstrong, Jesús García-Donás, Elizabeth M. Swisher, Anne Floquet, Gottfried E. Konecny, Iain A. McNeish, Clare L. Scott, T. Cameron, Lara Maloney, Jeff Isaacson, Sandra Goble, Caroline A. Grace, Thomas C. Harding, Mitch Raponi, James Sun, Kevin Lin, Heidi Giordano, Jonathan A. Ledermann, Martin Buck, Andrew Dean, Michael Friedländer, Jeffrey C. Goh, Paul R. Harnett, Ganessan Kichenadasse, Clare L. Scott, Hannelore Denys, Luc Dirix, Ignace Vergote, Laurie Elit, Prafull Ghatage, Amit M. Oza, Marie Plante, Diane Provencher, Johanne I. Weberpals, Stephen Welch, Anne Floquet, Laurence Gladieff, Florence Joly, Alexandra Léary, Alain Lortholary, Jean‐Pierre Lotz, Jacques Médioni, Olivier Trédan, Benoît You, Ayşe Balat, Claudia Hänle, Petra Krabisch, Tanja Neunhöffer, Martin Pölcher, Pauline Wimberger, A Amit, Svetlana Kovel, Michelle Leviov, Tamar Safra, Ronnie Shapira‐Frommer, Salomon M. Stemmer, Alessandra Bologna, Nicoletta Colombo, Domenica Lorusso, Sandro Pignata, Roberto Sabbatini, Giovanni Scambia, Stefano Tamberi, Claudio Zamagni, Peter C.C. Fong, Anne O’Donnell, Margarita Amenedo, A. Casado Herráez, Jesús García-Donás, E.M. Guerra, Ana Oaknin, Isabel Palacio, Ignacio Romero, A Sanchez, Susana Banerjee, Andrew R. Clamp, Yvette Drew, Hani Gabra, D Jackson, JA Ledermann, Iain A. McNeish, C. A. Parkinson, Melanie Powell, Carol Aghajanian
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
Éric Pujade-Lauraine, Felix Hilpert, B. Weber, Alexander Reuß, Andrés Poveda, Gunnar B. Kristensen, Roberto Sorio, Ignace Vergote, Petronella O. Witteveen, Aristotelis Bamias, Deolinda Pereira, Pauline Wimberger, Ana Oaknin, Mansoor Raza Mirza, Philippe Follana, David T. Bollag, Isabelle Ray‐Coquard
Improved Survival with Bevacizumab in Advanced Cervical Cancer
Krishnansu S. Tewari, Michael W. Sill, Harry J. Long, Richard T. Penson, Helen Huang, Lois M. Ramondetta, Lisa M. Landrum, Ana Oaknin, Thomas Reid, Mario M. Leitão, Helen E. Michael, Bradley J. Monk